#  Biomaterial scaffold-based immunotherapy platforms licensed to Novartis 

 





March 31, 2018

 

 

- [ News ](/news-categories/news)
 
 

 

 The Wyss Institute at Harvard Universtiy and Dana-Farber Cancer Institute have entered a licensing and collaboration agreement with Novartis to develop our biomaterial systems to delivery next generation immunotherapies. Our approach uses an injectable or implantable biomaterial scaffold that recruits and trains the body's endogenous immune cells to identify and kill a patient's own cancerous cells. A big congratulations to [Dave](/people/david-mooney), [Omar](/people/omar-ali), and team! We've still got a lot of work to do.

 For more information on our technology, please have a look at the [immunotherapy research section](/immune-therapies-and-cancer).

 To view the Novartis press release, click [here](https://www.novartis.com/news/media-releases/novartis-teams-harvard-develop-next-generation-biomaterial-systems-deliver-immunotherapies).

 Photo credit: Wyss Institute at Harvard University



 

 

 



 

 

 Share on:- [     Facebook ](#)
- [     Twitter ](#)
- [     Linkedin ](#)